Document Detail

Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease.
MedLine Citation:
PMID:  20508519     Owner:  NLM     Status:  MEDLINE    
PURPOSE OF REVIEW: Inflammatory bowel disease (IBD) is a debilitating and widespread immune-mediated illness of unknown etiology. Current treatments are modestly successful and with significant side-effects. The purpose of this review is to summarize the current understanding of mechanisms of action underlying the anti-inflammatory actions of conjugated linoleic acid (CLA) and n-3 polyunsaturated fatty acids (PUFAs) in IBD.
RECENT FINDINGS: Nutrition-based interventions that target peroxisome proliferator-activated receptors (PPARs) such as dietary CLA and n-3 PUFA have demonstrated anti-inflammatory efficacy in animal models of IBD. Clinical data on n-3 PUFA in IBD remains generally unimpressive, although results of a recent human study demonstrate that IBD remission can be maintained by maintaining the n-3: n-6 ratio more than 0.65 via n-3 PUFA intervention. In mice, CLA prevented inflammation-driven colorectal cancer by activating PPAR gamma and modulating regulatory T cells and macrophages. CLA is the subject of an ongoing clinical study in Crohn's disease patients.
SUMMARY: Compelling evidence demonstrates that n-3 PUFA and CLA prevent or ameliorate IBD in animal models. However, this basic knowledge has not been translated into novel nutrition-based clinical interventions. For both compounds there is an urgent need for placebo-controlled, large-scale, multicenter clinical trials.
Josep Bassaganya-Riera; Raquel Hontecillas
Related Documents :
16627889 - Breast milk fatty acids may link innate and adaptive immune regulation: analysis of sol...
15487769 - Effects of selenium deficiency on fatty acid metabolism in rats fed fish oil-enriched d...
7911819 - Interconversion of alpha-linolenic acid in rat intestinal mucosa: studies in vivo and i...
1909049 - Dietary n-6 fatty acids inhibit the incorporation of dietary n-3 fatty acids in thrombo...
9657459 - Fatty acid composition of the belgian diet: estimates derived from the belgian interuni...
8103979 - Interaction of dietary protein and alpha-linolenic acid on polyunsaturated fatty acid c...
21110089 - Functions of chondroitin sulfate and heparan sulfate in the developing brain.
6736039 - Novel surface lipids of diapausing manduca sexta pupae. long chain oxoalcohol esters of...
42459 - Amino acids as neurotransmitters of corticofugal neurones in the rat: a comparison of g...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current opinion in clinical nutrition and metabolic care     Volume:  13     ISSN:  1473-6519     ISO Abbreviation:  Curr Opin Clin Nutr Metab Care     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-12     Completed Date:  2011-02-16     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9804399     Medline TA:  Curr Opin Clin Nutr Metab Care     Country:  England    
Other Details:
Languages:  eng     Pagination:  569-73     Citation Subset:  IM    
Laboratory of Nutritional Immunology and Molecular Nutrition, Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Colorectal Neoplasms / drug therapy,  immunology
Dietary Supplements*
Fatty Acids, Omega-3 / pharmacology,  therapeutic use*
Inflammatory Bowel Diseases / drug therapy*,  metabolism
Linoleic Acids, Conjugated / pharmacology,  therapeutic use*
Macrophages / drug effects,  metabolism
Peroxisome Proliferator-Activated Receptors / metabolism*
T-Lymphocytes, Regulatory / drug effects,  metabolism
Grant Support
R01 AT004308-04/AT/NCCAM NIH HHS
Reg. No./Substance:
0/Fatty Acids, Omega-3; 0/Linoleic Acids, Conjugated; 0/Peroxisome Proliferator-Activated Receptors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel c...
Next Document:  Perioperative haemodynamic therapy.